280 related articles for article (PubMed ID: 33980589)
1. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
[TBL] [Abstract][Full Text] [Related]
2. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
[TBL] [Abstract][Full Text] [Related]
3. DNGR-1(+) dendritic cells are located in meningeal membrane and choroid plexus of the noninjured brain.
Quintana E; Fernández A; Velasco P; de Andrés B; Liste I; Sancho D; Gaspar ML; Cano E
Glia; 2015 Dec; 63(12):2231-48. PubMed ID: 26184558
[TBL] [Abstract][Full Text] [Related]
4. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
5. Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity.
Giampazolias E; Schulz O; Lim KHJ; Rogers NC; Chakravarty P; Srinivasan N; Gordon O; Cardoso A; Buck MD; Poirier EZ; Canton J; Zelenay S; Sammicheli S; Moncaut N; Varsani-Brown S; Rosewell I; Reis e Sousa C
Cell; 2021 Jul; 184(15):4016-4031.e22. PubMed ID: 34081922
[TBL] [Abstract][Full Text] [Related]
6. A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells.
Oba T; Hoki T; Yamauchi T; Keler T; Marsh HC; Cao X; Ito F
J Immunol; 2020 Oct; 205(7):1867-1877. PubMed ID: 32848036
[TBL] [Abstract][Full Text] [Related]
7. Cross-presentation of dead-cell-associated antigens by DNGR-1
Balam S; Kesselring R; Eggenhofer E; Blaimer S; Evert K; Evert M; Schlitt HJ; Geissler EK; van Blijswijk J; Lee S; Reis e Sousa C; Brunner SM; Fichtner-Feigl S
Eur J Immunol; 2020 Dec; 50(12):2041-2054. PubMed ID: 32640051
[TBL] [Abstract][Full Text] [Related]
8. The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice.
Iborra S; Izquierdo HM; Martínez-López M; Blanco-Menéndez N; Reis e Sousa C; Sancho D
J Clin Invest; 2012 May; 122(5):1628-43. PubMed ID: 22505455
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
[TBL] [Abstract][Full Text] [Related]
10. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
Chang LY; Lin YC; Mahalingam J; Huang CT; Chen TW; Kang CW; Peng HM; Chu YY; Chiang JM; Dutta A; Day YJ; Chen TC; Yeh CT; Lin CY
Cancer Res; 2012 Mar; 72(5):1092-102. PubMed ID: 22282655
[TBL] [Abstract][Full Text] [Related]
11. DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues.
Poulin LF; Reyal Y; Uronen-Hansson H; Schraml BU; Sancho D; Murphy KM; Håkansson UK; Moita LF; Agace WW; Bonnet D; Reis e Sousa C
Blood; 2012 Jun; 119(25):6052-62. PubMed ID: 22442345
[TBL] [Abstract][Full Text] [Related]
12. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant
Oba T; Kajihara R; Yokoi T; Repasky EA; Ito F
Cancer Res; 2021 Dec; 81(24):6183-6195. PubMed ID: 34666993
[TBL] [Abstract][Full Text] [Related]
14. Myosin II Synergizes with F-Actin to Promote DNGR-1-Dependent Cross-Presentation of Dead Cell-Associated Antigens.
Schulz O; Hanč P; Böttcher JP; Hoogeboom R; Diebold SS; Tolar P; Reis e Sousa C
Cell Rep; 2018 Jul; 24(2):419-428. PubMed ID: 29996102
[TBL] [Abstract][Full Text] [Related]
15. Mevalonate Blockade in Cancer Cells Triggers CLEC9A
Xu F; Wang Z; Zhang H; Chen J; Wang X; Cui L; Xie C; Li M; Wang F; Zhou P; Liu J; Huang P; Xia X; Xia X
Cancer Res; 2021 Sep; 81(17):4514-4528. PubMed ID: 34266895
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
Spranger S; Dai D; Horton B; Gajewski TF
Cancer Cell; 2017 May; 31(5):711-723.e4. PubMed ID: 28486109
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
18. DNGR-1 in dendritic cells limits tissue damage by dampening neutrophil recruitment.
Del Fresno C; Saz-Leal P; Enamorado M; Wculek SK; Martínez-Cano S; Blanco-Menéndez N; Schulz O; Gallizioli M; Miró-Mur F; Cano E; Planas A; Sancho D
Science; 2018 Oct; 362(6412):351-356. PubMed ID: 30337411
[TBL] [Abstract][Full Text] [Related]
19. Loss of secreted gelsolin enhances response to anticancer therapies.
Lim KHJ; Giampazolias E; Schulz O; Rogers NC; Wilkins A; Sahai E; Strid J; Reis e Sousa C
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36162919
[TBL] [Abstract][Full Text] [Related]
20. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
